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We tested the efficacy of DNAvaccines expressing the duck hepatitis B virus (DHBV) pre-surface (pre-S/S) and surface (S) proteins in modifying
the outcome of infection in 14-day-old ducks. In two experiments, Pekin Aylesbury ducks were vaccinated on days 4 and 14 of agewith plasmidDNA
vaccines expressing either the DHBV pre-S/S or S proteins, or the control plasmid vector, pcDNA1.1Amp. All ducks were then challenged
intravenously on day 14 of age with 5 × 107 or 5 × 108 DHBV genomes. Levels of initial DHBV infection were assessed using liver biopsy tissue
collected at day 4 post-challenge (p.c.) followed and immunostained for DHBV surface antigen to determine the percentage of infected hepatocytes.
All vector vaccinated ducks challenged with 5 × 107 and 5 × 108 DHBV genomes had an average of 3.21% and 20.1% of DHBV-positive hepatocytes
respectively at day 4 p.c. and 16 out of 16 ducks developed chronic DHBV infection. In contrast, pre-S/S and S vaccinated ducks challenged with
5 × 107 DHBV genomes had reduced levels of initial infection with an average of 1.38% and 1.93% of DHBV-positive hepatocytes at day 4 p.c.
respectively and 10 of 18 duckswere protected against chronic infection. The pre-S/S and the SDNAvaccinated ducks challengedwith 5 × 108 DHBV
genomes had an average of 31.5% and 9.2% of DHBV-positive hepatocytes on day 4 p.c. respectively and only 4 of the 18 vaccinated ducks were
protected against chronic infection. There was no statistically significant difference in the efficacy of the DHBV pre-S/S or S DNA vaccines. In
conclusion, vaccination of young ducks with DNA vaccines expressing the DHBV pre-S/S and S proteins induced rapid immune responses that
reduced the extent of initial DHBV infection in the liver and prevented the development of chronic infection in a virus dose-dependent manner.
© 2006 Elsevier Inc. All rights reserved.Keywords: Human hepatitis B virus; Duck hepatitis B virus; DNA vaccine; DHBV surface antigen; Humoral immunity; Cell-mediated immunityIntroduction
The human hepatitis B virus (HBV) is the prototype member
of the family Hepadnaviridae. More than 2000 million
individuals alive today have been infected with HBV. Of
these, ∼350 million people remain chronically infected,
resulting in significant rates of chronic liver disease, cirrhosis
and in some cases, progression to primary liver cancer or
hepatocellular carcinoma (Lavanchy, 2004). Individuals chron-
ically infected with HBV generally have low to undetectable
cytotoxic T lymphocyte (CTL) responses to HBV antigens.⁎ Corresponding authors. Fax: +61 8 8303 7532.
E-mail addresses: darren.miller@adelaide.edu.au (D.S. Miller),
allison.jilbert@adelaide.edu.au (A.R. Jilbert).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.02.037Conversely, those who resolve their HBV infection mount
strong, multi-HBV epitope-specific humoral and cell-mediated
immunity (CMI) (Bertoletti and Naoumov, 2003).
Vaccination of adults and children using the current
recombinant HBV surface antigen (HBsAg) vaccine produced
in yeast has been implemented in many countries (Maugh,
1981). Vaccination with recombinant HBsAg elicits strong
humoral immune responses but only weak CMI. Approxi-
mately 95% of vaccinated adults sero-convert achieving anti-
HBs antibody titers of >10 mIU per ml after two booster
immunizations (Maugh, 1981). These antibodies provide
protection against HBV challenge in a majority of recipients
but provide no therapeutic effect in chronically infected
patients (Michel et al., 2001). Vaccination with the recombi-
nant HBsAg vaccine is not likely to be effective in all areas
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controlled temperatures for both storage and distribution. If
eradication of HBV is to be successful, future vaccine
strategies need to include countries with high endemicity of
HBV infection and to concentrate primarily on infants
because they commonly develop chronic HBV infection
(Bertoletti and Naoumov, 2003). It is certain that a simpler,
cheaper and more effective HBV vaccine needs to be
developed for infection to be controlled and/or eradicated in
a reasonable timeframe.
In theory, vaccines based on DNA technology could provide
the basis for the development of effective therapeutic anti-HBV
vaccine(s). DNA vaccines are relatively cheap and simple to
make because they require little downstream processing, they are
stable at ambient temperatures and provide long-lasting
protective immunity to HBV, woodchuck hepatitis virus
(WHV) and DHBV (Lu et al., 1999; Prince et al., 1997; Rollier
et al., 1999; Triyatni et al., 1998). Unlike conventional sub-unit
vaccines that typically generate strong humoral immunity but
weak CMI, DNA vaccines elicit both humoral and CMI,
including the induction of antigen-specific CTL (Davis et al.,
1997) stimulated by the presentation of peptide fragments,
derived from endogenously synthesized and degraded antigen, in
context withMajorHistocompatibility ComplexClass I (MHC I)
products (Davis et al., 1998). Furthermechanisms underlying the
response to DNA vaccines are the innate immune response to
immunostimulatory non-methylated CpG motifs unique to
bacterial and viral DNA. The response to non-methylated CpG
DNA is mediated by Toll Like Receptor-9 (TLR-9), a member of
a family of pattern recognition receptors involved in innate
immunity (Medzhitov et al., 1997). Upon recognition by TLR-9,
an intracellular signalling cascade is activated resulting in the
stimulation of B-cells, macrophages and dendritic cells, and
production of cytokines (Akira et al., 2001).
DNA vaccines designed to combat HBV infection are likely
to have the greatest impact if they induce protective immune
responses in young or newborn individuals. To date little work
has been done to investigate if DNA vaccines elicit protective
immune responses in young animals.
DHBV infection of Pekin Aylesbury ducks provides a good
model for studying vaccines and developing protocols aimed at
controllingHBVinfection in humans. In our previous studies, we
defined the age- and dose-related outcomes of DHBV infection
and showed that, like humans infected with HBV, young ducks
are highly susceptible to the development of chronic DHBV
infection (Foster et al., 2005; Jilbert et al., 1998, 1996; Meier et
al., 2003; Miller et al., in press). However, the susceptibility of
newly hatched ducks to the development of chronic DHBV
infection decreases rapidly after hatching, presumably mirroring
the ability of the immune response to resolve DHBV infection in
older ducks (Foster et al., 2005; Jilbert et al., 1998). In two
separate studies, 14-day-old ducks inoculated with 4 × 104
DHBV genomeswere able to clear the virus resulting in transient
DHBV infection, while inoculation with 1 × 106 and 1 × 108
DHBVgenomes resulted in the development of chronic infection
(Foster et al., 2005; Jilbert et al., 1998), highlighting the
important effect of virus dose on infection outcome.The effect of virus dose on infection outcome was also
recently demonstrated through use of the nucleoside analogue
entecavir (ETV; now also known as baraclude); treatment of 14-
day-old ducks with ETV for 14 or 49 days did not prevent initial
DHBV infection of the liver but restricted the spread of virus
infection and prevented the development of chronicity (Foster et
al., 2005).
In previous DNA vaccine studies, adult ducks were
vaccinated with DNA vaccines expressing either the large
envelope protein, pre-S/S (Rollier et al., 1999; Triyatni et al.,
1998) or S (Triyatni et al., 1998). However, neither study
determined if pre-S/S or S DNA vaccines provided more
effective protection against the development of chronic
infection since adult ducks readily clear DHBV infection
resulting in low rates of chronic DHBV infection, even when
inoculated with 2 × 1011 DHBV genomes (Jilbert et al., 1998).
In the Triyatni study, adult ducks vaccinated with a DHBV S
DNA vaccine had faster rates of removal of inoculated virus
from the bloodstream following virus challenge and reduced
numbers of DHBV-infected cells compared to ducks vaccinated
with a DHBV pre-S/S vaccine (Triyatni et al., 1998). Although
the smaller S vaccine was not tested in the Rollier study,
vaccination with a pre-S/S construct provided significant
protection (Rollier et al., 1999). Since this time there has been
considerable controversy as to which of the constructs provides
the greatest protective efficacy against DHBV challenge.
The only previous study that investigated the ability of DNA
vaccines expressing DHBV surface proteins to induce immune
responses in young ducks demonstrated that ducks injected
intramuscularly with a single 100 μg dose of DHBV pre-S/S
DNA vaccine at 3 days of age developed detectable anti-
DHBsAg (anti-DHBs) antibodies approximately 4 weeks later.
However, these animals were not challenged with DHBV to test
the protective efficacy of the pre-S/S vaccine (Rollier et al.,
2000a). In other studies, maternally transferred antibodies from
DHBV pre-S/S DNA-immunized ducks protected offspring
against DHBV infection (Rollier et al., 2000b) suggesting a key
role for anti-DHBs antibodies in virus neutralization and
protection.
More recently, we assessed the protective efficacy of whole
cell vaccines expressing DHBV core antigen (DHBcAg) (Miller
et al., in press). In these studies, virus challenge led to DHBV
infection of similar numbers of infected hepatocytes in both the
vaccinated and non-vaccinated groups, confirming that anti-
DHBc antibodies induced by the vaccine did not restrict DHBV
infection and that DHBcAg-specific CMI was responsible for
targeting of infected cells and preventing the development of
chronic DHBV infection.
The aim of the current study was to determine if injection of
DNA vaccines expressing either the 37 kDa DHBV pre-S/S or
the 17 kDa S proteins could restrict DHBV infection of the liver
through induction of virus-specific humoral and CMI and lead to
different outcomes of infection in young ducks. The study thus
aimed to determine if inclusion of the pre-S domain provided
additional protection over DNA vaccines expressing only the
DHBV S protein. Two challenge doses were used as we
suspected from previous work (Foster et al., 2005) that
Table 1
Summary of DNA vaccination and DHBV challenge experiments 1 and 2
5 × 107 DHBV vge a 5 × 108 DHBV vge a
Duck
#
Vaccine b Day
4 p.c. c
Autopsy c Duck
#
Vaccine b Day
4 p.c. c
Autopsy c
Experiment 1
1075 preS/S 0.7 <0.001 d 1095 preS/S 50 >95
1086 preS/S 0.9 <0.001 1097 preS/S 35 >95
1093 preS/S <0.001 <0.001 1099 preS/S 67 >95
1063 S 2.3 >95 1069 S 1.4 <0.001
1123 S <0.001 <0.001 1124 S 3.3 >95
1067 S <0.001 <0.001 1073 S 9.1 >95
1051 Vector 2.4 >95 1057 Vector 22 >95
1053 Vector 4.9 >95 1059 Vector 43 >95
1055 Vector 3.4 >95 1061 Vector 35 >95
Experiment 2
88 preS/S 0.7 <0.001 91 preS/S 0.694 <0.001
89 preS/S 0.17 >95 92 preS/S 0.54 <0.001
90 preS/S 0.51 <0.001 93 preS/S 1.31 >95
211 preS/S 4.6 >95 208 preS/S 15 >95
212 preS/S 5.0 >95 209 preS/S 38 >95
213 preS/S 0.8 <0.001 210 preS/S 18 >95
94 S 0.29 >95 97 S 16 >95
95 S 0.9 >95 98 S 20 >95
96 S 1.0 >95 99 S 17 >95
205 S 5.0 >95 202 S 0.27 <0.001
206 S 2.0 <0.001 203 S 14.7 >95
207 S 0.012 <0.001 204 S 14.5 >95
82 Vector 1.4 >95 86 Vector 4.0 >95
83 Vector 2.6 >95 87 Vector 3.6 >95
84 Vector 1.5 >95 222 Vector 7.5 >95
225 Vector 4.6 >95 221 Vector 6.8 >95
224 Vector 4.0 >95 220 Vector 10.0 >95
a Ducks were challenged at day 14 of age with either 5 × 107 or 5 × 108 DHBV
genomes.
b Ducks were vaccinated at day 4 and day 14 of age with 250 μg of pre-S/S, S
or vector DNA vaccines.
c The percentage of DHBsAg-positive hepatocytes was detected by
immunoperoxidase staining of liver tissue. Liver tissue was collected by
biopsy on day 4 p.c. and by autopsy, at week 9 p.c. in Experiment 1, and week 5
p.c. in Experiment 2.
d The lower limit of sensitivity of detection of DHBsAg-positive hepatocytes
was 0.001%.
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infecting the ducks with either 5 × 107 and 5 × 108 DHBV
genomes was to quantitate, in vivo, the virus neutralizing ability
of the antibodies generated by the vaccines.
In the present study, DNAvaccines expressing DHBV pre-S/
S and S were administered to ducks at days 4 and 14 of age. The
ducks were also challenged on day 14 of age with a dose of
either 5 × 107 or 5 × 108 DHBV genomes, doses of DHBV that
are 50–500 times higher than those previously shown to cause
chronic DHBV infection in 14-day-old ducks (Foster et al.,
2005; Jilbert et al., 1998) and the ducks were monitored to
assess the extent of DHBV infection of the liver at day 4 p.c. and
the outcome of DHBV infection.
Results
Two experiments were performed. Experiment 1 involved
use of 3 ducks per group and it was concluded that the protective
efficacy of both the pre-S/S and S vaccines was better at the
lower challenge dose of 5 × 107 DHBV genomes. Due to the low
number of ducks, it was difficult to determine which of the two
vaccine constructs provided the best protection from chronic
infection. Therefore, a second larger experiment involved use of
6 ducks per group under the same conditions as Experiment 1.
Experiment 1
DHBV-infected and DHBV surface antigen (DHBsAg)-
positive hepatocytes were detected in liver biopsy tissue
collected at day 4 p.c. using anti-DHBV pre-S monoclonal
antibodies, 1H.1 (Pugh et al., 1995). Although not statistically
significant, liver tissue from the pre-S/S and S DNA vaccinated
ducks challenged with 5 × 107 DHBV genomes had lower
numbers of DHBsAg-positive hepatocytes at day 4 p.c.
(average: 0.8%, 2.3%; range: <0.001–5% and <0.001–2.3%,
respectively) than the vector-injected control ducks challenged
with the same dose (average: 3.6%; range: 2.4–4.9%) (Table 1).
Analysis of liver tissue collected at autopsy (week 9 of age)
revealed that in 3 of 3 ducks vaccinated with pre-S/S DNA and
2 out of 3 ducks vaccinated with DHBV S DNA, the infection
was transient as all these five ducks were protected from the
development of chronic DHBV infection (Table 2). In contrast,
3 out of 3 vector-injected control ducks developed chronic
DHBV infection with >95% of hepatocytes staining DHBsAg-
positive at autopsy (Tables 1, 2). The levels of serum DHBsAg
were assessed by ELISA. In concordance with the results from
analysis of liver tissue, all three pre-S/S (1075, 1086, 1093) and
2 of the 3 (1123, 1067) S vaccinated ducks challenged with
5 × 107 genomes had no detectable DHBsAg in the serum at any
time and were protected from chronic infection (Fig. 1).
Vaccination with the DHBV pre-S/S and S vaccines was not as
effective in preventing chronic DHBV infection when the
challenge dose was increased 10-fold to 5 × 108 DHBV genomes.
The pre-S/S and SDNAvaccinated ducks challengedwith 5 × 108
DHBV genomes had DHBsAg-positive hepatocytes at day 4 p.c.
(average: 50.7% and 4.6%; range: 35–67% and 0.54–38%,
respectively) compared to the vector-injected control duckschallenged with the same dose (average 33.3%; range: 22–43%).
None of the pre-S/S DNAvaccinated ducks, and only one out of
three (1069) S DNA vaccinated ducks, was protected from the
development of chronic DHBVinfection (Table 2). The protected
duck (1069) had 1.4% of DHBsAg-positive hepatocytes at day 4
p.c. and resolved its DHBVinfection (Table 1). As expected, all of
the vector-injected animals challenged with 5 × 108 DHBV
genomes also developed chronic DHBV infection with >95% of
hepatocytes staining positive for DHBsAg at autopsy (Table 1).
Levels of serum DHBsAg were also tested. All of the vector-
injected and the pre-S/S and S vaccinated ducks challenged with
5 × 108 DHBV genomes had detectable serum DHBsAg at some
time during the course of the experiment (Fig. 1) including duck
1069 that resolved its infection but had transient DHBsAg in the
serum at week 4 of age.
Serum was also tested for the presence of anti-DHBs
antibodies. Although there were no detectable anti-DHBs
antibodies prior to DHBV challenge, those ducks that received
Table 2
The number of ducks protected against the development of chronic DHBV infection in Experiments 1 and 2
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antibody responses and higher titers of anti-DHBs antibodies
(Fig. 2). All ducks that resolved their DHBV infection had
readily detectable anti-DHBs antibodies.
Experiment 2
As in the first experiment, the pre-S/S and S DNAvaccinated
ducks challenged with 5 × 107 DHBV genomes generally had
lower numbers of DHBsAg-positive hepatocytes at day 4 p.c.
(average 1.96% and 1.57%; range: 0.17–5% and 0.012–5%)
respectively than the vector-injected control ducks challenged
with the same dose (average 2.82%; range: 1.4–4.6%) (Table 1).
Analysis of liver tissue collected at autopsy (week 5 of age)
revealed that three of the six ducks vaccinated with DHBV pre-
S/S (88, 90, 213) and two of the six (206, 207) S DNA
vaccinated ducks resolved their DHBV infection, whereas the
remaining ducks developed chronic DHBV infection (Tables 1,
2). All five of the vector-injected ducks also developed chronic
DHBV infection with >95% of hepatocytes staining DHBsAg-
positive at autopsy. The levels of serum DHBsAg were assessed
by ELISA. In concordance with the results from analysis of
liver tissue, three of six pre-S/S vaccinated (88, 90, 213) and
two of six S vaccinated ducks (206, 207) challenged with
5 × 107 DHBV genomes had no detectable DHBsAg in the
serum at any time and resolved their DHBV infection (Fig. 3).
In contrast, all of the vector-injected ducks challenged with
5 × 107 DHBV genomes had detectable serum DHBsAg at
some time during the course of the experiment (Fig. 3).
Again, vaccination with the DHBV DNA vaccines was less
effective in preventing chronic DHBV infection when the
challenge dose of DHBV was increased 10-fold to 5 × 108DHBV genomes. At day 4 p.c., the percentage of hepatocytes
staining DHBsAg positive was reduced, although not signifi-
cantly (Table 2), in both the DHBV pre-S/S and S vaccinated
ducks (average: 12.3%, 13.7%; range: 0.54–38 and 0.27–20%,
respectively) when compared to the ducks injected with the
vector-injected controls (average: 6.8%; range: 4–10%) (Table
1). In this experiment, two out six pre-S/S DNA (91 and 92) and
only one of the six S DNAvaccinated ducks (202) resolved their
DHBV infection (Table 2). All of the vector-injected ducks
challenged with 5 × 108 DHBV genomes progressed to chronic
DHBV infection with >95% of hepatocytes staining positive for
DHBsAg at autopsy (Tables 1, 2).
Two out of six pre-S/S vaccinated ducks challenged with
5 × 108 DHBV genomes (91 and 92) and one S vaccinated duck
(202) had no detectable DHBsAg in the serum at any time and
resolved their DHBV infection (Fig. 3). All 5 vector-injected
ducks challenged with 5 × 108 DHBV genomes had detectable
serum DHBsAg at some time during the course of the
experiment (Fig. 3).
Again in this experiment, no anti-DHBs antibodies were
detected prior to DHBV challenge. However, the DNAvaccines
primed the immune response indicated by the higher titers of
anti-DHBs antibodies in the vaccinated ducks compared to the
vector-injected controls. Again, all the ducks that resolved their
DHBV infection had readily detectable anti-DHBs antibodies
(Fig. 4).
Statistical analysis
Statistical analysis of the combined data from Experiments 1
and 2 was performed using the Cochran–Mantel–Haenszel
statistic to determine if there was an association between vaccine
Fig. 1. Serum levels of DHBsAg in Experiment 1. Ducks were injected on days 4 and 14 of age with either pre-S/S vaccine (A, D), S DNA (B, E) or vector
(pcDNA1.1 Amp) (C, F). On day 14 of age, ducks were challenged with either 5 × 107 DHBV genomes (A, B, C) or 5 × 108 DHBV genomes (D, E, F). = DNA
injection, = DNA injection and DHBV challenge. The cut-off for DHBsAg-positive samples was set at two standard deviations above the average background,
obtained by assaying uninfected duck serum.
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ing virus challenge and the outcome of infection. At day 4 p.c.,
the pre-S/S and S groups showed a decrease in the percentage of
DHBsAg-positive hepatocytes compared to controls (1.38 and
1.93% compared to 3.21% at a challenge dose of 5 × 107).
However, the differences were not statistically significant, and
require more animals to reach significance.
The outcome of DHBV infection was also assessed using the
Cochran–Mantel–Haenszel statistic and at a virus dose of 5 ×
107 both the pre-S/S and S DNA vaccines provided statistically
significant protection from the development of chronic infection
when compared to vaccination with the vector alone (P < 0.001
and P = 0.0036, respectively; Table 2). However, no statistical
difference was found between the pre-S/S and S DNA vaccines(P = 0.1202, Table 2). Interestingly, when virus dose was in-
creased to 5 × 108 DHBV genomes, neither the pre-S/S nor S
DNAvaccines provided statistically significant protection com-
pared to vector alone (P = 0.1320 and P = 0.1320, respectively).
Statistical analysis was also performed by constructing a
Receiver Operating Characteristic (ROC) curve to link the
percentage of DHBsAg-positive hepatocytes at day 4 p.c. to the
probability of developing chronic DHBV infection (data not
shown). In both Experiments 1 and 2 where a duck had >2% of
hepatocytes infected at day 4 p.c., the duck invariably
developed chronic DHBV infection. ROC curve statistical
analysis confirmed this finding. Where a cut point of 2.3% of
DHBsAg-positive hepatocytes at day 4 p.c. was chosen, it
revealed a sensitivity of 83% and specificity of 100% (data not
Fig. 2. Serum levels of anti-DHBs antibodies as detected by ELISA. Ducks were injected on days 4 and 14 of age with either Pre-S/S vaccine (A, D), S DNA (B, E)
or vector (pcDNA1.1 Amp) (C, F). On day 14 of age, ducks were challenged with either 5 × 107 DHBV genomes (A, B, C) or 5 × 108 DHBV genomes (D, E, F).
= DNA injection, = DNA injection and DHBV challenge. The cut-off for anti-DHBs antibody-positive samples was set at two standard deviations above the
average background, obtained by assaying uninfected duck serum. The lower limit of sensitivity of the assay is a 1/100 dilution of duck serum.
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indicated a high level of accuracy of the diagnostic test.
Although the reverse does not hold true, i.e. some ducklings
were unable to resolve their DHBV infection with considerably
lower infected hepatocytes at day 4 p.c., the finding suggests
that the ability of the immune system to resolve DHBV infection
is linked to an upper-threshold number. Once that thresh-hold
number of infected hepatocytes is reached, the animal will
progress to chronic infection independent of vaccine status.
Discussion
Our vaccine regime was designed to test DNA vaccines in
young animals. We wished to determine if DNA vaccinesexpressing DHBV surface antigens could reduce the number of
initially DHBV-infected cells (even 10 days after a single dose
of DNA vaccine), and if vaccination could provide protection
against the development of chronic DHBV infection following
challenge with doses of DHBV 50–500 times higher than those
known to result in chronic infection in 14-day-old ducks (Jilbert
et al., 1998; Foster et al., 2005). The second dose of vaccine was
administered at the same time as the virus challenge (day 14 of
age) to boost both humoral and CMI, to assist in restricting the
spread of infection and helping to target and eliminate infected
hepatocytes. It is interesting to consider that the second dose of
vaccine may not be needed since the first dose had primed the
immune response, which was then boosted by challenge with
infectious virus. It is possible that the protection seen with these
Fig. 3. Serum levels of DHBsAg as detected by ELISA. Ducks were injected on days 4 and 14 of age with either pre-S/S vaccine (A, D), S DNA (B, E) or vector
(pcDNA1.1 Amp) (C, F). On day 14 of age, ducks were challenged with either 5 × 107 DHBV genomes (A, B, C) or 5 × 108 DHBV genomes (D, E, F). = DNA
injection, = DNA injection and DHBV challenge. The cut-off for DHBsAg-positive samples was set at two standard deviations above the average background,
obtained by assaying uninfected duck serum.
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finding in itself may have important implications in the
development of cheap, protective vaccines using DNA
technology.
It was shown that vaccination of ducks with either pre-S/S or
S expressing DNA constructs elicited a rapid immune response
that was effective in providing protection against the develop-
ment of chronic infection using a challenge dose of 5 × 107
DHBV genomes. Protection was observed in six out of nine pre-
S/S and four out of nine S vaccinated ducks, respectively.
Although there appeared to be a slight increase in the protective
efficacy of the pre-S/S construct, the difference was not
statistically significant (Table 2). This dose is at least 50 times
greater than the dose needed to cause chronic infection in non-immunized control animals (Foster et al., 2005; Jilbert et al.,
1998). The mechanism(s) responsible for this protection are
being investigated.
The inability to detect anti-DHBs antibodies prior to
challenge maybe due to the relative immaturity of the
immune system at the time of vaccination or to the
insensitivity of the anti-DHBs ELISA. Evidence for priming
of the immune system following DNA vaccination is
indicated by higher levels of anti-DHBs antibodies detected
in the serum of DNA vaccinated ducks following DHBV
challenge. Interestingly, all the ducks that were protected from
the development of chronic infection developed higher titers
of anti-DHBs antibodies than the vector-injected controls
(Figs. 2, 4).
Fig. 4. Serum levels of anti-DHBs antibodies as detected by ELISA. Ducks were injected on days 4 and 14 of age with either pre-S/S vaccine (A, D), S DNA (B, E)
or vector (pcDNA1.1 Amp) (C, F). On day 14 of age, ducks were challenged with either 5 × 107 DHBV genomes (A, B, C) or 5 × 108 DHBV genomes (D, E, F).
= DNA injection, = DNA injection and DHBV challenge. The cut-off for anti-DHBs antibody-positive samples was set at two standard deviations above the
average background, obtained by assaying uninfected duck serum. The lower limit of sensitivity of the assay is a 1/100 dilution of duck serum.
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were observed in this and in previous studies of chronic DHBV
infection (Foster et al., 2005; Jilbert et al., 1998, 1996; Miller et
al., in press). We believe this is due to a dynamic balance
between virus infection and the immune response, with
fluctuating levels of anti-DHBs reflecting unsuccessful attempts
by the immune response to control infection. For example, the
rise in anti-DHBs at week 3 could represent a “turning-point”
where the humoral immune response produces anti-DHBs that
bind to DHBsAg to form immune complexes that are efficiently
removed from the circulation. Levels of DHBsAg fall at this
time, but due to exhaustion or depletion of the humoral immuneresponse, levels of DHBsAg eventually rise again. Decreases in
DHBsAg at week 3 might also be caused by induction of a
cellular immune response and immune attack on infected
hepatocytes. Although we see no decrease in the percentage of
infected hepatocytes at this time, levels of virus replication and
release may transiently decrease due to the death of infected
hepatocytes and their replacement by proliferation of other
infected cells. Ducks with chronic infection experience
continued immune stimulation and this could also explain the
late rise in the titer of anti-DHBs antibodies.
Another plausible explanation for the fluctuating levels of
anti-DHBs is the inherent difficulty in detecting antibodies in
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antibodies were present in the serum but were masked in the
ELISA by DHBsAg (Foster et al., 2005). Co-detection of
HBsAg and anti-HBs has also been observed in human HBV
infection (Surelia and Boxall, 1990; Tsai et al., 1998, 1995).
Both the pre-S/S and S expressing DNA vaccines provided
significant protection when compared to vaccination with the
plasmid vector alone, albeit, only at the lower challenge dose of
5 × 107 DHBV genomes (Tables 1, 2). The ducks that were
protected generally showed a reduction in the number of
infected hepatocytes at day 4 p.c.; we propose that either low
levels of neutralizing antibodies prevented initial infection, or
that rapid onset of a CMI suppressed infection within this
timeframe. Although the presence of anti-DHBs antibodies in
the serum of the vaccinated ducks could result in virus
neutralization, both at the time of virus inoculation and during
release, reducing cell-to-cell spread of virus to adjacent cells,
there were no significant differences in the percentage of
hepatocytes infected at day 4 p.c. More experiments with larger
groups of animals are required to further address this issue.
At the time of DHBV challenge, the weight of the ducks was
∼500 g. Previous experiments have determined that the duck
liver comprises ∼3% of total body weight and that the number
of cells in each gram of duck liver is 7 × 108 (Jilbert et al.,
1992). Therefore, we estimate there are∼1.05 × 1010 cells in the
liver of 14-day-old ducks. We expect from these calculations
that the vector-injected ducks challenged with 5 × 107 or 5 × 108
DHBV genomes would have ∼0.48% and ∼4.8% liver cells
initially infected.
Recent observations in non-vaccinated 1-day-old ducks
challenged with 1500 DHBV genomes also show that the rate
of spread of DHBV infection throughout the liver is rapid, with
95% of hepatocytes becoming infected only 4 days after <0.1%
were initially infected (Meier et al., 2003). The rate of spread of
infection throughout the liver in the vector-injected 14-day-old
ducks in this current study appears to follow similar kinetics. At
day 4 p.c., liver tissue from the vector-injected ducks challenged
with 5 × 107 DHBV genomes contained 1.4–4.9% DHBsAg-
positive hepatocytes, a level five- to eight-fold higher than could
be expected from the original inoculum. Similarly, liver tissue
from the vector-injected ducks challenged with 5 × 108 DHBV
genomes contained 3.6–43% of DHBsAg-positive hepatocytes,
a level up to nine times higher than expected from the inoculum,
indicating rapid spread of DHBV infection from cell-to-cell. In
the ducks challenged with 5 × 107 DHBV genomes, vaccination
with both the pre-S/S and SDNAvaccines was effective in many
of the ducks reducing the number of hepatocytes infected on day
4 p.c. It is unclear whether the decrease in the number of
DHBsAg-positive hepatocytes in vaccinated animals was due to
a reduction in the infectivity of the inoculum caused by
antibodies present at the time of inoculation or a decrease in
the rate of spread of virus from cell-to-cell.
The protection afforded by DNA vaccination was probably
not due solely to antibody-mediated “neutralizing” immunity
because at day 4 p.c., almost all ducks had DHBV-infected
hepatocytes in the liver. It seems likely that both humoral and
CMI responses were responsible for the clearance of virus fromthese infected hepatocytes. Further studies are needed to define
the mechanisms operating in the resolution phase of DHBV
infection. Irrespective of the type of immune mechanism(s) that
is providing protection, the immunity induced was over-
whelmed by the larger challenge dose of 5 × 108 DHBV
genomes and no significant protection observed with either of
the two vaccine constructs (Table 2).
Although it is difficult to draw direct comparisons between
the immunocompetence of neonatal humans and 14-day-old
ducks, if similar immune-mediated mechanisms that result in
the reduction of DHBV-infected hepatocytes shortly after
challenge are also operational in humans, these results indicate
that DNA vaccination shortly after birth could be a cheap and
effective means to reduce mother to infant transmission of HBV
and to protect against newly emerging infectious disease.
Materials and methods
Animals
The Pekin Aylesbury ducks (Anas domesticus platy-
rhynchos) were purchased at 1-day of age from two commercial
hatcheries. Neither DHBV nor maternal antibodies to DHBV
have ever been detected in the DHBV-negative flock. All
animal handling procedures and protocols were assessed,
approved and carried out in accordance with the guidelines of
the University of Adelaide and Institute of Medical and
Veterinary Science animal ethics committees and the National
Health and Medical Research Council (NHMRC) of Australia.
Preparation of DHBV stocks
DHBV stocks were derived using pooled serum 34-day-old
congenitally DHBV-infected ducks infected with the Austra-
lian strain of DHBV (AusDHBV) (Triyatni et al., 2001). The
serum was filtered through a 0.2 μM filter, aliquoted and
stored at −80 °C, and found as previously described to contain
5 × 109 DHBV genomes/ml and 50 μg/ml of DHBsAg (Jilbert
et al., 1996).
Vaccination regime
The DHBV pre-S/S and S genes were cloned into
pcDNA1.1Amp as previously described (Triyatni et al.,
1998). In two separate experiments, groups of DHBV-negative
ducks were injected with 250 μg of the DHBV pre-S/S or S
DNA vaccine or the plasmid vector (pcDNA1.1 Amp;
Invitrogen), diluted in 0.9% NaCl, into the anterior quadriceps
muscle at day 4 of age. At day 14 of age, the ducks were injected
with a second dose of 250 μg of the pre-S/S or S vaccine or
vector alone and challenged intravenously (i.v.) on the same day
with either 5 × 107 or 5 × 108 DHBV genomes.
Analysis of serum and liver tissue
Serum samples were collected weekly and assayed for levels
of total anti-DHBs IgY antibodies and DHBsAg by ELISA
168 D.S. Miller et al. / Virology 351 (2006) 159–169(Jilbert et al., 1998, 1996; Miller et al., 2004, in press). To assess
the extent of DHBV infection in the liver, a wedge biopsy was
collected from each duck on day 4 p.c. Liver tissue samples
were also taken from all ducks at autopsy at week 9 of age
(Experiment 1) or week 5 of age (Experiment 2). Tissue
fixation, embedding, sectioning and immunoperoxidase stain-
ing of DHBsAg were performed as previously described (Jilbert
et al., 1998, 1996; Miller et al., 2004, in press; Triyatni et al.,
1998) using anti-pre-S monoclonal antibodies, 1H.1 (Pugh et
al., 1995). Hepatocytes staining positive for cytoplasmic
DHBsAg were counted using an eyepiece with a graticule.
For each duck, 10 representative grid fields of 250 × 250 μm
were counted and the number of DHBsAg-positive hepatocytes
was expressed as a percentage of the average total hepatocyte
nuclei (counterstained with hematoxylin) in the same fields with
a minimum sensitivity of detection of 0.001% (Foster et al.,
2005; Meier et al., 2003; Miller et al., in press).
Statistical analysis
The Cochran–Mantel–Haenszel statistic was used to deter-
mine if there was an association between the resolution of
DHBV infection and vaccine group (pre-S/S, S or vector) with
adjustment for each experiment. The normally distributed
outcome of the number of the percentage of DHBsAg-positive
hepatocytes was analyzed using a mixed model ANOVA to
allow for repeated measures over time with adjustment for each
experiment. Post hoc testing was used to look at pair-wise
comparisons between the vaccine groups with no adjustment
made for multiple comparisons. Significance was assessed at
the 5% level. A Receiver Operating Characteristic (ROC) curve
was also constructed linking the percentage of DHBsAg-
positive hepatocytes at day 4 p.c. to the probability of
developing chronic DHBV infection. This in turn was used to
determine the sensitivity and specificity to determine the
optimal cut point for the percentage of DHBsAg-positive
hepatocytes at day 4 p.c. All analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC, USA).
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